Invention Grant
- Patent Title: EP300/CREBBP inhibitor
-
Application No.: US16625578Application Date: 2018-06-21
-
Publication No.: US11274100B2Publication Date: 2022-03-15
- Inventor: Hiroyuki Naito , Yoshiko Kagoshima , Hideaki Funami , Akifumi Nakamura , Masayoshi Asano , Makoto Haruta , Takashi Suzuki , Jun Watanabe , Ryutaro Kanada , Saito Higuchi , Kentaro Ito , Akiko Egami , Katsuhiro Kobayashi
- Applicant: Daiichi Sankyo Company, Limited
- Applicant Address: JP Tokyo
- Assignee: Daiichi Sankyo Company, Limited
- Current Assignee: Daiichi Sankyo Company, Limited
- Current Assignee Address: JP Tokyo
- Agency: Christensen O'Connor Johnson Kindness PLLC
- Priority: JPJP2017-121454 20170621
- International Application: PCT/JP2018/024476 WO 20180621
- International Announcement: WO2018/235966 WO 20181227
- Main IPC: C07D471/04
- IPC: C07D471/04
Abstract:
The present invention provides a compound having excellent histone acetyl transferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.
Public/Granted literature
- US20210171520A1 EP300/CREBBP INHIBITOR Public/Granted day:2021-06-10
Information query
